

Quarterly Business Update & Investor Calls

Highlights for the quarter ended 30 September 2017

- Further strengthening of InvitroCue's commercial capabilities and scientific leadership with two senior appointments made to management team
- Two articles published in prestigious *Nature* journal by clinical and scientific advisors at InvitroCue
- Recognition of InvitroCue's strong intellectual property portfolio with award win from Singapore government's IP office

October 31, 2017 – InvitroCue Limited (ASX:IVQ), a leading healthcare bio-analytic solutions provider, yesterday released its Appendix 4C – Quarterly Cash Flow Report for the quarter ended 30 September 2017.

Revenue from customers totalled S\$227k for the quarter, as InvitroCue continued to progress its business development and marketing efforts in markets such as Europe, USA and Australia.

On September 28, InvitroCue announced two senior appointments to its management team with Dr Sunny Tan appointed Senior VP, Scientific Affairs and Corporate Development, and Dr Ramanuj DasGupta appointed Chief Scientific Officer (Non-Executive), Onco-PDO. These appointments are made at an important time in the company's development as InvitroCue continues to evaluate collaborations and commercial opportunities globally.

During September, studies based on the work of Dr Ramanuj DasGupta, Chief Scientific Officer (Non-Executive) Onco-PDO, and InvitroCue clinical adviser Dr Narayanan Gopalakrishna Iyer, Senior Oncologist at the National Cancer Center/Singapore General Hospital, were published in *Nature*, one of the world's most cited and prestigious scientific journals.

The first article, 'Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time', published under *Nature Communications*, suggests an alternative concept towards bringing truly individualized treatment (precision oncology) to the clinic using patient-derived models for drug screening. This study was led by the team of Dr Ramanuj DasGupta.

The second article, 'Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma', published under *Nature Medicine*, validated a novel biomarker that may help determine efficacy of tyrosine kinase inhibitors in head, neck and lung cancers, thereby facilitating a personalized patient-selection strategy to guide treatment in the clinic. Work for this study was led by Dr Narayanan Gopalakrishna Iyer, who is head of cancer and neck surgery at the National Cancer Center Singapore as well as a member of InvitroCue's clinical advisory board. The laboratory and clinical team of Dr DasGupta supported additional work carried out as part of this research.

Lastly, on August 29, InvitroCue received an award for its use of intellectual property at the WIPO – IPOS IP Awards 2017 in Singapore. The awards are jointly presented by the World

Intellectual Property Organization (WIPO) and the Intellectual Property Office of Singapore (IPOS), recognising companies who have effectively used intellectual property to grow their business, collaborate externally and enter partnerships.

InvitroCue Managing Director, Dr Steven Fang commented:

“Over the last quarter our expanded management team have focused on continuing to grow our businesses and revenues, while also evaluating strategic collaborations to address important clinical needs in the cancer space globally. We are proud to have built a high calibre management team and network of advisors, as evidenced by recent scientific publications focused on their work. Our unique approach to personalised medicine continues to receive increasing interest, and we look forward to updating investors on our growth trajectory during the next quarter and beyond”.

Investor conference calls

Shareholders and investors are invited to join one of two conference calls being hosted by Managing Director, Steven Fang on Monday November 6 to discuss activity during the quarter.

Australia / New Zealand

Monday, November 6, 2017

Access Code: 523-393-973

11.30 AM Sydney - +61 2 8355 1050

1.30 PM Auckland - +64 9 280 6302

To join the meeting from your computer, tablet or smartphone [click here](#).

Europe / UK

Monday, November 6, 2017

Access Code: 970-256-765

9.00 AM Munich - +49 692 5736 7317

9.00 AM Zurich - +41 225 4599 78

9.00 AM London - +44 20 3713 5028

To join the meeting from your computer, tablet or smartphone [click here](#).

- ENDS -

For more information, please contact:

Martin D. Bach, VP Operations

T: +65 6460 0490

martind.bach@invitrocue.com

About Invitrocue

Invitrocue is a leading healthcare bio-analytic solutions including *in vitro* cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. The technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine). Invitrocue's technology originated in Singapore's Agency for Science, Technology and Research (A*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.